Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of
human hepatic clearance fromin vivoanimal experiments andin vitrometabolic
studies with liver microsomes from animals and humans. Drug Metab Dispos
2001;29:1316–1324.
Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in
predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and
humansin vivoandin vitro. Drug Metab Dispos 2003;31:580–588.
Nnane IP, Damani LA. Involvement of cytochrome P450 and the flavin-containing
monooxygenase(s) in the sulphoxidation of simple sulphides in human liver
microsomes. Life Sci 2003;73:359–369.
Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic
microsomal intrinsic clearance data: An examination ofin vitrohalf-life approach
and nonspecific binding to microsomes. Drug Metab Dispos 1999;11:1350–1359.
Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in
liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, andin vitro–in
vivocorrelation. Drug Metab Dispos 2000;28:1069–1076.
Obach RS. The prediction of human clearance from hepatic microsomal metabolism
data. Curr Opin Drug Discov Devel 2001;4:36–44.
Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ,
Wastall P. The prediction of human pharmacokinetic parameters from preclinical
andin vitrometabolism data. J Pharmacol Exp Ther 1997;283:46–58.
Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome
P450-mediated biotransformation reactions using a substrate depletion approach.
Drug Metab Dispos 2002;30:831–837.
Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a
‘‘well-stirred’’ model and a ‘‘parallel tube’’ model. Influence of hepatic blood flow,
plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic
drug clearance. J Pharmacokinet Biopharm 1977a;5:625–653.
Pang KS, Rowland M. Hepatic clearance of drugs. II. Experimental evidence for
acceptance of the ‘‘well-stirred’’ model over the ‘‘parallel tube’’ model using lidocaine in
the perfused rat liverin situpreparation. J Pharmacokinet Biopharm 1977b;5:655–680.
Raucy JL, Lasker JM. Isolation of P450 enzymes from human liver. Methods Enzymol
1991;206:577–587.
Reddy A, Heimbach T, Freiwald S, Smith D, Winters R, Michael S, Surendran N, Cai
H. Validation of a semi-automated human hepatocyte assay for the determination
and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal
2005;37:319–326.
Richard B, Fabre G, De Sousa G, Fabre I, Rahmani R, Cano JP. Interspecies
variability in mitoxantrone metabolism using primary cultures of hepatocytes
isolated from rat, rabbit and humans. Biochem Pharmacol 1991;41:255–262.
Roberts MS, Rowland M. Correlation betweenin vitromicrosomal enzyme activity and
whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm
Pharmacol 1986a;38:177–181.
Roberts MS, Rowland M.A dispersion model of hepatic elimination: 2. Steady-state
considerationsinfluence of hepatic blood flow, binding within blood, and hepatocel-
lular enzyme activity. J Pharmacokinet Biopharm 1986b;14:261–288.
444 DETERMINATION OF METABOLIC RATES AND ENZYME KINETICS